Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TroVax + docetaxel
- Development stage
- Discontinued
- Lead developer
- Oxford BioMedica
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
TroVax + docetaxel is a combination therapy composed of **TroVax**, a cancer vaccine based on modified vaccinia Ankara (MVA) engineered to express the tumor-associated antigen **5T4**, and **docetaxel**, a cytotoxic chemotherapy agent. TroVax is designed to provoke an immune response, especially stimulating antibody and cytotoxic T cell responses against tumor cells expressing 5T4. Docetaxel is a well-established taxane chemotherapeutic that inhibits microtubule depolymerization, arresting the cell cycle and promoting apoptosis. This combination has been studied in castration-resistant prostate cancer (CRPC), with the rationale that docetaxel provides rapid tumor burden reduction while TroVax induces immunological memory and durable tumor control. Early-phase clinical studies report the combination is well tolerated, with evidence of enhanced immune responses and possible improvement in progression-free survival compared to docetaxel alone[1][3][5].
- Other names
- TroVax + docetaxel
02
Targets
TPBG (Trophoblast glycoprotein)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TroVax + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TroVax + docetaxel.